The ORANGE II PLUS randomized controlled trial has provided the first high-quality evidence comparing laparoscopic and open hemihepatectomy. While the laparoscopic approach offers faster recovery and better postoperative quality of life, uncertainty has persisted regarding its economic value. The accompanying health–economic analysis by Olij et al.1 addresses this gap, demonstrating that laparoscopic hemihepatectomy incurs higher intraoperative costs but generates meaningful postoperative savings and greater quality-adjusted life-year gains. With an incremental cost-effectiveness ratio well below accepted thresholds, the procedure emerges as a cost-effective strategy within modern health systems. These findings support broader adoption of laparoscopic hemihepatectomy while highlighting the need to optimize operative efficiency, refine the use of disposable instruments, and continue investing in structured training pathways. Collectively, the ORANGE II PLUS data establish laparoscopic hemihepatectomy as not only a clinical advancement, but also a sound investment in patient recovery and long-term value.
